Slovenian study seeks to personalize melanoma immunotherapy
NCT ID NCT07407166
First seen Feb 14, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study looks at how effective first-line immunotherapy is for people with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia. Researchers will track tumor shrinkage, time to progression, and side effects, and analyze blood, stool, and body fluids to find biomarkers that predict who benefits most. The goal is to improve personalized treatment decisions for future patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Oncology Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.